Latest news
Samsung Bioepis launches OPUVIZ pre-filled syringe biosimilar across Europe - Indian Pharma PostIndian Pharma Post · Mon, 10 Aug 2026 13:26:43 GMTSamsung Bioepis lines up Opuviz syringe as European aflibercept rivals multiply - The Pharma LetterThe Pharma Letter · Mon, 10 Aug 2026 12:41:14 GMTSamsung Bioepis Files South Korea's First Approval for Biosimilar of Merck's $32.4 Billion Cancer Drug Keytruda - finance.biggo.comfinance.biggo.com · Mon, 10 Aug 2026 09:15:00 GMTSamsung Bioepis Files Korea’s First Keytruda Biosimilar Application - businesskorea.co.krbusinesskorea.co.kr · Mon, 10 Aug 2026 09:13:02 GMTSamsung Bioepis files first Korea application for Keytruda biosimilar - CHOSUNBIZ - ChosunbizChosunbiz · Mon, 10 Aug 2026 07:36:00 GMTSamsung Bioepis Applies for Domestic Approval of Keytruda Biosimilar - asiae.co.krasiae.co.kr · Mon, 10 Aug 2026 07:33:49 GMTSamsung Bioepis Launches OPUVIZ™ (Aflibercept) 40 mg/mL Pre-filled Syringe Across Europe - businesskorea.co.krbusinesskorea.co.kr · Mon, 10 Aug 2026 06:15:19 GMTSamsung Bioepis battles Janssen, Pfizer, Novartis in global biosimilar suits - CHOSUNBIZ - ChosunbizChosunbiz · Mon, 10 Aug 2026 00:42:00 GMT